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Diabetic nephropathy is a leading cause of end-stage renal disease, which is increasing in incidence worldwide, despite intensive
treatment approaches such as glycemic and blood pressure control in patients with diabetes mellitus. New therapeutic strategies
are needed to prevent the onset of diabetic nephropathy. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated
nuclear transcription factors that play important roles in lipid and glucose homeostases. These agents might prevent the
progression of diabetic nephropathy, since PPAR agonists improve dyslipidemia and insulin resistance. Furthermore, data from
murine models suggest that PPAR agonists also have independent renoprotective eﬀects by suppressing inﬂammation, oxidative
stress, lipotoxicity, and activation of the renin-angiotensin system. This review summarizes data from clinical and experimental
studies regarding the relationship between PPARs and diabetic nephropathy. The therapeutic potential of PPAR agonists in the
treatment of diabetic nephropathy is also discussed.
Copyright © 2008 Shinji Kume et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The incidence and prevalence of type 2 diabetes mellitus
(DM) have been increasing worldwide since the 1980s,
and this rise is estimated to continue in the future [1, 2].
Diabetic nephropathy is a common complication of DM
and represents one of the major challenges for modern
nephrology as the most common cause of end-stage renal
disease, accounting for about 40% of new cases [3, 4]. The
increasing prevalence of DM and its complications including
diabetic nephropathy have therefore become a major health
problem worldwide, and new therapeutic strategies to pre-
vent diabetic nephropathy are urgently needed.
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors belonging to the
nuclear hormone receptor superfamily. They were originally
cloned from rodent liver while screening for molecular
mediators of peroxisome proliferation [5, 6]. Three isoforms
have been cloned (PPARα,P P A R β/δ,a n dP P A R γ)a n dc h a r -
acterized. Each has a unique expression pattern and ligand-
binding speciﬁcity, as well as distinct metabolic functions
[7]. PPARs regulate diverse cell functions, including fatty
acid metabolism, adipocyte diﬀerentiation, inﬂammation,
atherosclerosis, and cell cycle [8–11]. PPARα plays an impor-
tant role in lipid metabolism in several tissues including liver
and kidney [12]. PPARβ/δ is associated with cell survival
and colon carcinogenesis [13] and was recently implicated
as an important regulator of mitochondrial biogenesis and
subsequent lipid metabolism in skeletal muscle [14]. PPARγ
plays a pivotal role in adipogenesis, and its activation
by thiazolidinediones (TZDs) improves insulin sensitivity
via this role in adipocyte diﬀerentiation [15]. Accordingly,
TZDs are widely used as oral antidiabetic agents in patients
with type 2 diabetes [15, 16]. It is clear that substantial
experimental and clinical research is still needed to clarify
the role of PPARγ in the whole body physiology and the
pathophysiology of various diseases such as diabetes, obesity,
hypertension, atherosclerosis, and cancer.
In addition to the demonstrated physiological roles,
several clinical and experimental studies have implicated
PPARs in the pathogenesis of diabetic nephropathy. This
review summarizes these clinical and experimental data with
a particular focus on the therapeutic potential of PPAR
modulators in diabetic nephropathy.2 PPAR Research
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Figure 1: Structure and action of PPARs. (a) Domain structure of human PPARs. (b) Molecular mechanism of PPARs. After ligand binding,
PPARs undergo conformational change with RXR and cofactors.
2. STRUCTURE OF PPARs
PPAR was initially identiﬁed in a mouse cDNA library in
1990 [6], and since then three PPARs have been cloned:
PPARα,P P A R β/δ,a n dP P A R γ (Figure 1(a))[ 7]. PPARγ
mRNA has three splicing forms derived from a single gene
in human [17]. There are no splicing variants of PPARα
or PPARβ/δ mRNA. Two PPARγ protein isoforms result
from the translation of each of the three PPARγ mRNAs
to produce PPARγ1a n dγ2[ 18], with both PPARγ1a n d
PPARγ3 mRNAs giving rise to the same protein, PPARγ1.
PPARγ2 is the larger of the two isoforms, with 30 additional
N-terminal amino acids. Due to diﬀerent promoter usage,
PPARγ1andPP ARγ2ha v ediﬀerentexpressionpatterns[19].
All PPARs possess four domains similar to those found
in other nuclear hormone receptors [5, 20]: an NH2-
terminal ligand-independent transactivation domain (acti-
vation function-1 (AF-1)), which regulates PPAR activity
(A/B domain) [21, 22]; a DNA-binding domain of 70
amino acids (two zinc ﬁngers) (DBD, C domain); a docking
domain for cofactors (D domain); a COOH-terminal region
containing the ligand-binding domain (LBD) and AF-2
domain (E/F domain). DBD and LBD are approximately
70% homologous among the three PPARs.
3. PPAR LIGANDS
PPARs are ligand-activated transcriptional factors belonging
to the nuclear hormone receptor superfamily, whereby
modulation of target gene transcription depends on the
binding of ligands to the receptor. PPARs form heterodimers
with the 9-cis retinoic acid receptor, retinoid X receptor
(RXRα). Activation of the PPAR:RXRα heterodimers by
PPAR ligands and/or RXR ligands triggers a conformational
change in the receptors. This in turn allows the heterodimers
tobindtoPPARresponsibleelementcontainingthesequence
AGGTCANAGGTCA in the promoter region of the target
genes, and thus modulate gene transcription (Figure 1(b)).
Many ligands including natural and synthetic com-
pounds have been identiﬁed for each PPAR isoform in
both functional (cell-based transactivation eﬃciency) and in
vitro interaction assays [8, 23]. The diﬀerent amino acids
sequences in the LBD of each PPAR provide the molecular
basis for ligand speciﬁcity. Each PPAR can accommodate
several structurally diverse ligands due to a large ligand-
binding pocket [24]. PPARα binds unsaturated fatty acids
with the highest aﬃnity of the three isoforms [25–28].
Natural ligands for PPARγ also include several unsaturated
fatty acids such as oleate, linoleate, eicosapentaenori and
arachidonic acids, and 15dPGJ2 [8, 23, 29, 30]. TZD
compounds such as troglitazone (was the ﬁrst agent of this
class on the market, but withdrawn due to liver toxicity),
ciglitazone, pioglitazone, and rosiglitazone act as synthetic
PPARγ ligands and promote adipocyte diﬀerentiation via
activation of the receptor [23, 31–35]. Termisaltan, an
angiotensin II type 1 receptor blocker (ARB), was recently
shown to bind PPARγ and reduce blood glucose levels [36,
37].Shinji Kume et al. 3
4. DISTRIBUTION OF PPARs IN KIDNEY
Expression of the three PPAR isoforms has been examined
in many species including Xenopus, rat, mouse, rabbit, and
human. PPARα is mainly expressed in tissues exhibiting high
catabolic rates of fatty acids such as adipose tissue, liver,
heart, and skeletal muscle [38, 39]. PPARβ/δ is ubiquitously
expressed, while PPARγ is highly expressed in white and
brown adipose tissues that store large amounts of fatty acids,
and in other selected tissues at low levels such as heart, liver,
immune cells (monocytes and macrophages), placenta, and
colon [40–42].
All three PPARs are expressed in the kidney [38, 41–
43]. PPARγ mRNA has been demonstrated in the medullary
collecting ducts and pelvic urothelium of kidney [44], as well
as in isolated glomeruli and cultured mesangial cells[45, 46].
PPARα and γ1, but not γ2, protein was detected in kidney
tissue by immunoblot analysis, while immunohistochemical
analysis revealed PPARα and γ1 proteins in the nuclei of
mesangial cells and epithelial cells in glomeruli, proximal
and distal tubules, the loop of Henle, medullary collecting
ducts, and the intima/media of renal vasculatures [47]. Large
amounts of PPARα have also been detected in proximal
tubular cells, and renal lipid metabolism is highly regulated
by PPARα [48]. In contrast to PPARα,P P A R γ protein is
highly expressed in the nephron segment, predominantly in
collecting ducts, implicating PPARγ in systemic water and
sodium retention [49, 50].
5. EXPERIMENTAL (ANIMAL) STUDIES
PPARγ is the best characterized of the PPAR isoforms in
diabetic animal models. The ﬁrst evidence for a possible
renoprotective eﬀect of PPARγ agonists came 15 years ago,
with the TZD compound troglitazone decreasing urinary
albumin excretion and reducing blood pressure in obese
Zucker rats [51]. Further studies since then also showed
the beneﬁcial eﬀects of TZD compounds on renal injury in
type 1 and type 2 diabetic animal models, as summarized in
Table 1 [50,52–60].Severalexperimentalstudiesalsoshowed
similar or superior protection against diabetic nephropathy
for PPARγ agonists such as TZD, with results comparable to
otherrenoprotectiveagentssuchasrenin-angiotensinsystem
blockers.
PPARα is highly expressed in renal proximal tubules and
helps to maintain a sustained balance of energy production
and expenditure in the kidney [61] .T h er o l eo fP P A R α
in renal cortex lipid metabolism was demonstrated when
the activation of PPARα by cloﬁbrates induced expression
of β-oxidation enzymes [62]. In db/db type 2 diabetic
mice [63] and Zucker diabetic rats [64], treatment with
PPARα activator, fenoﬁbrate, improved urinary albumin
excretion rates and glomerular mesangial expansion. These
experimental studies suggest PPARα agonists as potentially
useful therapeutic agents for diabetic nephropathy.
6. HUMAN CLINICAL TRIALS
Several clinical trials of PPARγ agonists have been conducted
overthepastdecadethattogetherconﬁrmtherenoprotective
action of PPARγ (Table 2)[ 65–79]. PPARγ agonist, TZD,
is an approved therapeutic agent for glycemic control in
patients with type 2 DM, and thus is eﬀective in preventing
type 2 diabetic nephropathy. The beneﬁcial eﬀect of piogli-
tazone on urinary albumin excretion was also demonstrated
in large, multicenter intervention studies, which compared
the general eﬃcacy and safety of TZD agents to other oral
antidiabetic agents in patients with type 2 DM over 1 year.
Either pioglitazone or the antidiabetic, metformin, was given
to 639-randomized patients already receiving a sulfonylurea
[72]. Although the two regimens had comparable eﬀects on
glycemic control, urinary albumin excretion was reduced by
15% in the group receiving pioglitazone and increased by
2% in the metformin group. In another study from the same
group on drug-naive patients with type 2 DM, pioglitazone
signiﬁcantly reduced urinary albumin excretion, whereas
metformin had no eﬀect. A similar follow-up study showed
that administration of pioglitazone in those patients who
had previously received metformin therapy was associated
with a decreased urinary albumin excretion of 10%, whereas
another TZD compound, gliclazide, caused an increase of
6% [74]. Taken together, these data from both large and
small clinical studies showed that PPARγ agonists have a
beneﬁcial eﬀect on diabetic nephropathy compared to other
antidiabetic agents.
It should be noted that PPARγ agonists could potentially
cause heart failure due to the associated water retention.
Recent clinical trials in patients with impaired glucose tol-
erance (IGT) and/or impaired fasting glucose (IFG) showed
that rosiglitazone, which reduces the onset of diabetes,
also reduced the development of renal disease; however,
it increased the adverse risk of heart failure, compared to
ramipril [79]. Therefore, PPARγ agonists should be used
only with intensive monitoring of volume retention in
patients with cardiac risk factors.
Clinical evidence also suggests the beneﬁcial eﬀect of
PPARα ligands on diabetic nephropathy. Treatment of
type 2 diabetes-associated dyslipidemia with gemﬁbrozil,
an antidyslipidemic agent and PPARα activator, stabilized
urinary albumin excretion rates [80, 81]. In addition, a
large randomized controlled trial in 2005 determined that
long-term fenoﬁbrate therapy signiﬁcantly reduced the rate
of progression to albuminuria in patients with type 2 DM
[82]. Although not extensive, these clinical data suggest the
therapeutic eﬃcacy of PPARγ agonists in preventing diabetic
nephropathy.
6.1. EffectsofPPARγ ligandsondiabeticnephropathy
6.1.1. Improvinghyperglycemia
The Diabetes Control and Complications Trial (DCCT) and
the United Kingdom Prospective Diabetes Study (UKPDS)
suggested that the adverse eﬀects of hyperglycemia on
metabolic pathways are the main causes of long-term
complications such as kidney disease in diabetes [83, 84].
TZDs are a new class of oral antidiabetic agents used
widely to improve insulin resistance, hyperinsulinemia, and
hyperglycemia in patients with type 2 diabetes [85–87].4 PPAR Research
Table 1: Animal studies.
Authors TZD Animal model Duration Eﬀect on UAE Eﬀect on BP Other eﬀects
Model of type 1 diabetes
Fujii et al. [54]T r o STZ-induced diabetic rats 12 weeks ↓ NS ND
Isshiki et al. [56]T r o STZ-induced diabetic rats 12 weeks ↓ ND Hyperﬁltration ↓
Nicholas et al. [58]T r o STZ-induced diabetic rats 12 weeks ↓ NS ND
Yamashita et al. [60] Tro, pio STZ-induced diabetic
SHR rats
12 weeks ↓ NS
Loss of glomerular
basement membranes ↓
Model of type 2 diabetes
Yoshioka et al. [51]T r o Obese Zucker rats 4a n d8w e e k s ↓↓ ND
Fujiwara et al. [55]T r o Wistar fatty rats 24 weeks ↓↓ ND
Yoshimoto et al. [50]P i o Diabetic Wistar fatty rats 13 weeks ↓↓
Glomerulosclerosis ↓
intrarenal
arteriolosclerosis ↓
Tanimoto et al. [59]P i o Diabetic KK/Ta mice 4a n d8w e e k s ↓ NS Glomerular enlargement ↓
Buckingham et al. [53]R o s i Obese Zucker rats 4a n d9m o n t h s ↓↓
Glomerulosclerosis ↓
tubulointerstitial ﬁbrosis ↓
Baylis et al. [52]R o s i Obese Zucker rats 6m o n t h s ↓ NS
Glomerulosclerosis ↓
tubulointerstitial ﬁbrosis ↓
Khan et al. [57]R o s i Obese Zucker rats 12 weeks ↓↓ ND
TZD, thiazolidinedione; Tro, troglitazone; Pio, pioglitazone; Rosi, rosiglitazone; STZ, streptozotocin; SHR, spontaneously hypertensive rats; UAE, urinary
albumin excretion; BP, blood pressure; NS, no signiﬁcant eﬀects; ND: not determined; ↓, signiﬁcant reductions.
Since the improvement of hyperglycemia in such patients
can prevent the development and progression of diabetic
nephropathy, TZDs are potential protective agents for
nephropathy in type 2 diabetes patients and animal models
by virtue of their insulin-sensitizing action [66].
6.1.2. Loweringbloodpressurewithorwithout
improvedinsulinresistance
Hypertension is commonly linked to obesity and insulin
resistance [88]. TZDs have a possible antihypertensive eﬀect
through improvement of insulin resistance because insulin
sensitivity is related to blood pressure levels both in diabetic
animals and patients [50, 89–92]. On the other hand, PPARγ
ligands could directly aﬀect vascular function because of
their expression in endothelial cells and vascular smooth
muscle cells (VSMCs) [93–95]. Indeed, pioglitazone lowered
the blood pressure in 5/6 nephrectomized hypertensive rats,
and the eﬀect was not associated with insulin resistance
[96, 97]. The demonstrated antihypertensive eﬀects of TZDs
could involve the release of vasodilators such as nitric
oxide and prostaglandins [98], the decrease in fatty acid
levels, and/or modiﬁcation of vasoactive peptide synthesis
including endothelin-1 [47]. Recently, PPARγ downregu-
lated the expression of angiotensin II type 1 receptor and
in turn decreased vascular smooth muscle tone, thereby
reducingvascularcontractility[99].Althoughtheunderlying
functional mechanisms remain unclear, PPARγ expression
probably contributes to blood pressure regulation through
multiple mechanisms.
6.2. RenoprotectiveeffectsofPPARγ ligands
duetomechanismsotherthanchangesin
bloodglucoselevels
TZD treatment ameliorated renal abnormalities in strep-
tozotocin- (STZ-) induced diabetic rats, a type 1 diabetic
model,withoutchangingbloodglucoselevels[54,56].These
ﬁndings suggest that the protective eﬀects of PPARγ ligands
on diabetes-induced renal dysfunction are independent of
its insulin-sensitizing property. Multiple biochemical mech-
anisms have been proposed to explain the adverse eﬀects of
hyperglycemia in diabetes, and the eﬀects of PPARγ ligands
on each of these mechanisms is discussed below.
6.2.1. AmeliorationofDGK-DAG-PKCpathwayactivation
The diacylglycerol- (DAG-) protein kinase C- (PKC-) extra-
cellular signal-regulated kinase (ERK) pathway is enhanced
in mesangial cells cultured under high-glucose conditions
and in glomeruli isolated from streptozotocin- (STZ-)
induced diabetic rats [100–103]. In these animals, trogli-
tazone ameliorated the diabetes-associated increases in
glomerular ﬁltration rate, urinary albumin excretion, and
mRNA expressions of extracellular matrix (ECM) proteins
(ﬁbronectin and type IV collagen) and transforming growth
factor-β (TGF-β) without changing the blood glucose levels
[56]. These ﬁndings provided the ﬁrst evidence that PPARγ
ligands can protect glomerular function independent of
their insulin-sensitizing action. In mesangial cells cultured
under high-glucose conditions and in isolated glomeruli
from diabetic rats, it was conﬁrmed that TZDs inhibitedShinji Kume et al. 5
Table 2: Human clinical studies.
Authors subjects
(Type 2 DM)
n regimens Duration Eﬀect on UAE (%) Eﬀect on BP
(mmHg)
Sironi et al. [65] hyp 40 200mg toroglitazone versus plb 8w e e k s +11% −4/−3
Imano et al. [66] mA, hyp 30 400mg toroglitazone versus
500mg metformin
12 weeks −39%a −3/0
Nakamura et al. [67] mA or MA 32 400mg toroglitazone versus
5mg glibenclamide
12 months −67%ain mA 0% in MA −6c
Nakamura et al. [68] mA 45 30mg Pio versus 5mg
glibenclamide versus 0.6mg Vog
3m o n t h s −66%a −6/−4
Nakamura et al. [69] mA 28 30mg Pio versus plb 6m o n t h s −59%a −4c
Aljabri et al. [70] mA, hyp 62 30–45mg Pio versus isophane
insulin
16 weeks −44% −8/−5
Yanagawa et al. [71] mA, hyp 40 Pio versus Met or glibenclamide 12 weeks −45%a NA
Hanefeld et al. [72] mA, hyp 639 15–45mg Pio versus
850–2550mg metformin
12 months −15%a NA
Schernthaner et al. [73] hyp 1199 15–45mg Pio versus
850–2550mg metformin
12 months −19%a NA
Matthews et al. [74] hyp 630 15–45mg Pio versus 80–320mg
glibenclamide
12 months −10%a NA
Agarwal et al. [75] MA, hyp 44 Pio versus Glip 4m o n t h s −7% +3.7/+2.2
Lebovitz et al. [76] mA, hyp 493 4 or 8mg Rosi versus plb 26 weeks 4mg group: −14% 8mg
group: −22%a NA
Saraﬁdis et al. [77] hyp, mA 20 4mgRosi 6m o n t h s −35%a −5.4a/−4.1a
Pistrosch et al. [78] mA, hyp 19 non-mA patients: Rosi versus
Nat, mA patients: Rosi versus plb
12 weeks non-mA patients: +18%b,
mA patients: −66%a,b, NA
aSigniﬁcant changes from baseline levels or other groups;
bchange versus the group compared;
cmean change for systolic BP versus baseline in patients treated with the TZD.
DM, diabetes mellitus; hyp, hypertension; mA, microalbuminuria; MA, macroalbuminuria; Glip, glipizide; Nat, nateglinide; plb, placebo; Pio, pioglitazone;
Vog, voglibose; UAE, urine albumin excretion; NA, changes in blood pressure levels not applicable.
the accumulation of DAG and its subsequent activation of
the PKC-ERK pathway. Furthermore, another TZD, pioglita-
zone, also prevented DAG-PKC-ERK pathway upregulation
in mesangial cells exposed to high glucose [56]. Finally,
TZDs and potent PPARγ ligand, 15dPGJ2, increased the
protein expression of DGK to block DAG-PKC signaling in
endothelial cells [103].
6.2.2. Attenuationofoxidativestress
Increasedoxidativestressisobservedinrenalglomerulianda
variety of vascular and nonvascular tissues exposed to hyper-
glycemia [104–106]. Troglitazone has potent antioxidant
eﬀects, evident by it suppressing phosphoenolpyruvate gene
expression in vitro and scavenging reactive oxygen species in
vivo [107]. It also normalizes the decrease in plasma lipid
hydroperoxide concentration and increase of superoxide
dismutase activity in Otsuka Long-Evans Tokushima Fatty
rats, a type 2 diabetic animal model, and improves the
decreased skin blood ﬂow in STZ-induced diabetic rats [98,
108, 109]. Pioglitazone also reduces oxidative stress in the
kidney of alloxan-induced diabetic rabbits [110, 111]a n d
reduces renal lipid peroxides, urinary isoprostane excretion,
and expression of p47 phox and gp91 phox in high-fat diet-
i n d u c e do b e s er a t s[ 112].
6.2.3. Suppressionofinﬂammation
Hyperglycemia and the diabetic state can induce cytokine
production in some tissues. In diabetic nephropathy,
macrophages inﬁltrates appear in glomeruli and the inter-
stitial spaces between tubules [113, 114]. Both PPARα and
γ have potent anti-inﬂammatory eﬀects in macrophages
[115, 116]. The endogenous and potent PPARγ ligand,
15dPGJ2, is a natural metabolite derived from prostaglandin
(PG)D2, the most abundant prostaglandin in normal tissues
with the highest binding aﬃnity to PPARγ of the J-series
prostaglandins [117]. Several studies demonstrated that the
anti-inﬂammatory eﬀect of 15dPGJ2 or TZDs seems to be
regulatedthroughtranscriptionalinhibitionbybothPPARγ-
dependent [115, 116, 118]a n dP P A R γ-independent mecha-
nisms [119–121]. Nuclear factor-κB( N F - κB), a well-known
inﬂammatory transcription factor, is repressed by 15dPGJ2
in a PPARγ-independent manner [122]. It was also reported
that 15dPGJ2 inhibits interleukin-1β-( I L - 1 β-) induced
cyclooxygenase-2 expression and PGE2 production indepen-
dently of PPARγ activation in mesangial cells, by suppressing
ERK and c-Jun NH2-terminal kinase (JNK) pathways and
AP-1 activation [123]. Another TZD agent, ciglitazone,
inhibited platelet-derived growth factor-induced mesangial
cell proliferation without changing ERK activation, through6 PPAR Research
inhibiting the activation of serum response element directly
[124].
6.2.4. Modiﬁcationofatheroscleroticchanges
Renal atherosclerotic changes such as renovascular stenosis
and atheroemboli are common ﬁndings in elderly diabetic
patients and are known to accelerate renal dysfunction [125,
126]. PPARγ activation also may modify the progression
of atherosclerosis through multiple mechanisms including
foam cell diﬀerentiation, inﬂammatory reactions, and cell
proliferation [127]. The inﬁltrating monocytes take up
oxidized low-density lipoprotein (OxLDL) via scavenger
receptors, resulting in the accumulation of intracellular
lipids and generation of foam cells [127]. The OxLDL
scavenger receptor, CD36, is under direct control of PPARγ
[29, 30]. OxLDLs include natural PPARγ agonists such
as 9-hydroxyoctadecadienoic acid (HODE) and 13-HODE.
Furthermore, OxLDL induces the expression of PPARγ
[115], which has an anti-inﬂammatory eﬀect in monocytes
by reducing proinﬂammatory cytokine production [115]v i a
inhibition of proinﬂammatory transcription factors such as
NFκB, AP-1, and STATs [116]. PPARγ has other eﬀects on
atherosclerosis including induction of apoptosis in mono-
cytes [128], inhibition of VSMC proliferation [94, 129], and
suppression of matrix metalloproteinase-9 expression [130].
6.3. EffectsofPPARγ ligandsintubulartissue
Patients with diabetic nephropathy frequently show a
nephrotic state, whereby large quantities of albumin enter
the renal tubular system and carry with it a heavy load of
fatty acids. Albumin-bound fatty acids can activate PPARγ
and induce apoptosis of proximal tubular cells. PPARγ
agonists might inhibit tubular cell proliferation, whereas
activation of albumin-bound fatty acids is accompanied
by increased proliferation [131]. In particular, pioglitazone
increases the tubular cell albumin uptake and reverses
the expression of inﬂammatory and proﬁbrotic markers,
monocyte chemoattractant protein-1 (MCP-1) and TGF-β
[132].
7. INVOLVEMENT OF PPARα AND PPARβ/δ IN
DIABETIC NEPHROPATHY
PPARα agonists have renoprotective eﬀects as mentioned
above. One possible mechanism underlying PPARα action
on mesangial matrix production may be related to hyper-
glycemia or TGFβ signaling [133]. Cloﬁbrate directly inhib-
ited oxidative stress-induced TGFβ expression in mesangial
cells [133], while fenoﬁbrate downregulated TGFβ and
TGFβ receptors type II expression and decreased type IV
collagen accumulation in diabetic glomeruli, and inhibited
the production of PAI-1 in diabetic animals [63, 64].
PPARβ/δ is expressed equally in the renal cortex and
medulla, although the role of PPARβ/δ in the kidney
remains poorly understood [41]. Overexpression of this
isoform protected cultured medullary interstitial cells from
hypertonicity-induced cell death, suggesting that PPARβ/δ is
an important survival factor under hypertonic conditions in
renal medulla [134]. However, there are no reports regarding
the eﬀect of PPARβ/δ on diabetic nephropathy. Further
evidence from both clinical and experimental studies is
necessary to clarify the therapeutic potential of PPARβ/δ and
PPARα agonists in diabetic nephropathy.
Several recent studies suggested lipotoxicity from renal
lipid accumulation as a possible pathogenic mechanism
underlying certain forms of renal injury including diabetic
nephropathy [135–137]. PPARα regulates lipid metabolism
in the kidney [48], and PPARα knockout mice develop
severe interstitial lesions induced by fatty acid overload
[138]. PPARα agonists may, therefore, decrease lipotoxic-
ity and, consequently, inhibit the progression of diabetic
nephropathy. PPARβ/δ also regulates lipid metabolism and
particularly lipid oxidation in several tissues, although
its exact roles in the kidney remain unclear. Thus, both
PPARβ/δ and PPARα agonists could be implemented in
new therapeutic strategies designed to prevent diabetic
nephropathy by reducing renal lipotoxicity. Further studies
are required to prove this possibility.
8. CONCLUSION AND PERSPECTIVES
The increased incidence of diabetic nephropathy has become
a major health problem worldwide. As discussed in this
review, PPARs comprise a subfamily of nuclear recep-
tors and transcription factors that play critical roles in
modulating insulin resistance, hypertension, dyslipidemia,
obesity, hypertension, and inﬂammation. Given the close
relationship between PPAR activity and these metabolic
alterations, PPAR agonists are promising therapeutic agents
for diseases including type 2 diabetes, obesity, hypertension,
hyperlipidemia, and atherosclerosis. Fibrate PPARα agonists
and TZD PPARγ agonists are already used successfully as
clinically eﬀective hypolipidemic drugs and insulin sensitiz-
ers. PPARβ/δ agonists may provide additional insulin and
lipid modulators via their eﬀects on skeletal muscle. In
addition, there is an increasing evidence suggesting that all
three PPARs contribute to the metabolic control of renal
function and are involved in the pathogenesis of diabetic
nephropathy. PPARγ agonists are available as optional
therapeutic agents for nephropathy in type 2 diabetes. In the
near future, both PPARα and PPARβ/δ agonists might be
added to that strategy with further evidence that these agents
have a proven renoprotective eﬀect in diabetic animals and
patients.
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